SBE13 hydrochloride

• CAT Number: I000284
• CAS Number: 1052532-15-6
• Molecular Formula: C₂₄H₂₇ClN₂O₄.HCl
• Molecular Weight: 479.4
• Purity: ≥95%
• Target: PLK
• Solubility: DMSO: ≥ 42 mg/mL
• Storage: Store at -20°C
• IC50: 0.2 nM [1]
• InChI: InChI=1S/C24H27ClN2O4.ClH/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19;/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3;1H
• InChIKey: QBGSVDJLQQXEGG-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)CCNCC2=CC(=C(C=C2)OCC3=CN=C(C=C3)Cl)OC)OC.Cl

SBE13 hydrochloride (Cat.No:I000284) is a chemical compound that acts as a potent and selective inhibitor of Transforming Growth Factor-Beta (TGF-β) receptor I (ALK5). It has been studied for its potential therapeutic effects in fibrotic diseases and cancer. SBE13 hydrochloride shows promise as a targeted therapy for modulating TGF-β signaling pathways.

Reference

[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9.
[2]. Lange L, et al. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget. 2014 Apr 30;5(8):2263-75.
[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73.